Kyverna Therapeutics (NASDAQ:KYTX) Trading 6.7% Higher - Should You Buy?

Key Points

• Kyverna Therapeutics shares rose 6.7% to $8.72, despite trading volume running 41% below its average. The company remains unprofitable, with a negative P/E ratio and analysts forecasting a full-year loss.
• Analyst sentiment is mixed but broadly positive: five analysts rate KYTX a Buy and one rates it Sell, producing a “Moderate Buy” consensus and a $30 average price target—well above the current price.
• Kyverna exceeded quarterly EPS expectations, reporting a loss of $0.63 per share versus the $0.68 expected. The clinical-stage biotech is developing engineered regulatory T-cell therapies, led by a program targeting ulcerative colitis.

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) rose 6.7% during trading on Monday . The stock traded as high as $8.76 and last traded at $8.72. 546,245 shares were traded during mid-day trading, a decline of 41% from the average daily volume of 928,649 shares. The stock had previously closed at $8.17.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on KYTX shares. JPMorgan Chase & Co. lowered their price objective on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an "overweight" rating for the company in a research report on Wednesday, May 13th. HC Wainwright reaffirmed a "buy" rating and set a $25.00 target price on shares of Kyverna Therapeutics in a research report on Wednesday, June 3rd. Wall Street Zen lowered Kyverna Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 30th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Kyverna Therapeutics in a research note on Wednesday, June 24th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $30.00.

Kyverna Therapeutics Trading Up 6.7%

The company has a debt-to-equity ratio of 0.15, a quick ratio of 9.06 and a current ratio of 9.06. The company has a market capitalization of $539.24 million, a P/E ratio of -2.97 and a beta of 1.93. The company's fifty day simple moving average is $8.07 and its 200-day simple moving average is $8.43.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.05. Research analysts predict that Kyverna Therapeutics, Inc. will post -2.7 earnings per share for the current year.

Institutional Trading of Kyverna Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of KYTX. Legal & General Group Plc bought a new position in shares of Kyverna Therapeutics during the 2nd quarter worth approximately $36,000. Public Employees Retirement System of Ohio acquired a new stake in Kyverna Therapeutics in the third quarter valued at approximately $28,000. Federated Hermes Inc. grew its holdings in Kyverna Therapeutics by 36.6% in the fourth quarter. Federated Hermes Inc. now owns 20,705 shares of the company's stock worth $195,000 after purchasing an additional 5,547 shares during the last quarter. Rhumbline Advisers increased its position in shares of Kyverna Therapeutics by 22.0% during the first quarter. Rhumbline Advisers now owns 31,614 shares of the company's stock worth $61,000 after purchasing an additional 5,694 shares in the last quarter. Finally, Bank of America Corp DE increased its position in shares of Kyverna Therapeutics by 41.6% during the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company's stock worth $81,000 after purchasing an additional 6,400 shares in the last quarter. Institutional investors own 18.08% of the company's stock.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company's lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source